E102 Characterisation of patients with rheumatoid arthritis based on distinct patterns of pain improvement following treatment with filgotinib: a post hoc analysis of FINCH 1

作者：P. Taylor, Yoshiya Tanaka, L. Dron, K. Van Beneden, Tariq Daud, Gerd R. Burmester, B. Fautrel · 发表于：Rheumatology · 年份：2026 · DOI：10.1093/rheumatology/keag121.325

JAK inhibitors have been shown to ameliorate pain as well as inflammation in patients with rheumatoid arthritis (RA). The objective of this analysis was to identify distinct pain response trajectories over 12 months in patients treated with filgotinib in FINCH 1. FINCH 1 (NCT02889796) was a 52-week randomised controlled trial, in which patients with RA had an inadequate response to methotrexate. Patients reported pain on a visual analog scale (VAS), Moderate pain was defined as a VAS pain score of 40-60 mm, with scores >60 mm indicating severe pain. A group-based trajectory modelling approach was applied to identify groups of patients with similar pain response trajectories over a 12-month period. A total of 955 patients were included in the analysis. Among those receiving filgotinib 200 mg (n = 475), modelling produced five distinct groups of pain response trajectory. Groups A and B (45% of patients) had a rapid reduction in pain in the first 3 months, with improvements maintained over 12 months. Groups C and D (35% of patients) had a slower response but achieved a reduction in pain of approximately 50% after 6 months. Group E (20% of patients) had severe pain at baseline and persistent, moderate pain over 12 months. Median VAS pain score was <40 mm at Month 3 in Groups A, B and C (approximately 60% of patients overall) and at Month 6 in Groups A, B, C and D (80% of all patients). Median age and disease duration were similar across all groups at baseline. Lac...